A pooled analysis of four publications involving 574 participants indicated that the rate of AEs resulting in treatment discontinuation did not significantly differ between adult ITP patients receiving SYK and/or BTK inhibitors and those given placebo (OR 1.88; 95%CI: 0.75 – 4.73, p=0.18, I2 = 0%, random-effect model) (Figure 3D) (Table 3). Here, BTK is linked to autoimmune thrombocytopenic purpura.